Trial Profile
Anlotinib Plus Docetaxel Versus Docetaxel for Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer After Disease Progression on Platinum-based Therapy : a Multicentre, Double-blind, Randomised Explorative Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2022
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALTER-L018
- 13 Sep 2022 Results of pooled analysis of two studies (ALTER-L016: NCT03726736; ALTER-L018: NCT03624309) assessing efficacy and safety anlotinib plus docetaxel in the treatment of non-small cell lung cancer, presented at the 47th European Society for Medical Oncology Congress.
- 09 Aug 2022 Results of final analyses of ALTER-L018 presented at the 2022 World Conference on Lung Cancer
- 09 Aug 2022 Results of pooled analysis (n=73) assessing the efficacy and safety of anlotinib plus docetaxel in advanced NSCLC patients (pts) who had been pre-treated with ICIs presented at the 2022 World Conference on Lung Cancer